{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T10:24:07Z","timestamp":1755599047665},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2001,7]]},"DOI":"10.1007\/s11940-001-0040-7","type":"journal-article","created":{"date-parts":[[2007,6,4]],"date-time":"2007-06-04T14:29:09Z","timestamp":1180967349000},"page":"367-376","source":"Crossref","is-referenced-by-count":5,"title":["Ocular myasthenia gravis"],"prefix":"10.1007","volume":"3","author":[{"given":"Victoria S.","family":"Pelak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven L.","family":"Galetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"40_CR1","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1749-6632.1987.tb51317.x","volume":"505","author":"D Grob","year":"1987","unstructured":"Grob D, Arsura EL, Brunner NG, Nambe T: The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci 1987, 505:472\u2013499.","journal-title":"Ann N Y Acad Sci"},{"key":"40_CR2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ana.410140504","volume":"14","author":"CT Bever","year":"1983","unstructured":"Bever CT, Aquino AV, Penn AS, et al.: Prognosis of ocular myasthenia. Ann Neurol 1983, 14:516\u2013519.","journal-title":"Ann Neurol"},{"key":"40_CR3","first-page":"6","volume":"42","author":"JF Simpson","year":"1966","unstructured":"Simpson JF, Westerberg MR, Magee KR: Myasthenia gravis: an analysis of 295 cases. Acta Neurol Scand 1966, 42(suppl):6\u201319.","journal-title":"Acta Neurol Scand"},{"key":"40_CR4","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","volume":"330","author":"DB Drachman","year":"1994","unstructured":"Drachman DB: Myasthenia gravis. N Engl J Med 1994, 330:1797\u20131810.","journal-title":"N Engl J Med"},{"key":"40_CR5","first-page":"464","volume-title":"Neuro-ophthalmology: diagnosis and management","author":"GT Liu","year":"2001","unstructured":"Liu GT, Volpe NJ, Galetta SL: Eyelid and facial nerve disorders. In Neuro-ophthalmology: diagnosis and management. Philadelphia: WB Saunders Company; 2001:464\u2013512."},{"key":"40_CR6","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/mus.880090904","volume":"9","author":"DB Sanders","year":"1986","unstructured":"Sanders DB, Howard JF: AAEE minimonography #25: single-fiber electromyography in myasthenia gravis. Muscle Nerve 1986, 9:808\u2013819.","journal-title":"Muscle Nerve"},{"key":"40_CR7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ana.410120303","volume":"12","author":"JJ Kelly","year":"1982","unstructured":"Kelly JJ, Daube JR, Lennon VA, et al.: The laboratory diagnosis of mild myasthenia gravis. Ann Neurol 1982, 12:238\u2013242.","journal-title":"Ann Neurol"},{"key":"40_CR8","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/mus.880180904","volume":"18","author":"A Rivero","year":"1995","unstructured":"Rivero A, Crovetto L, Lopex L, et al.: Single fiber electromyography of extraocular muscles: a sensitive method for the diagnosis of ocular myasthenia gravis. Muscle Nerve 1995, 18:943\u2013947.","journal-title":"Muscle Nerve"},{"key":"40_CR9","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1749-6632.1981.tb33764.x","volume":"377","author":"D Grob","year":"1981","unstructured":"Grob D, Brunner NG, Namba T: The natural course of myasthenia gravis and effect of therapeutic measures. Ann N Y Acad Sci 1981, 377:652\u2013669.","journal-title":"Ann N Y Acad Sci"},{"key":"40_CR10","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1749-6632.1976.tb47723.x","volume":"274","author":"KC Fischer","year":"1976","unstructured":"Fischer KC, Schwartzman RJ: Oral corticosteroids in the treatment of ocular myasthenia gravis. Ann N Y Acad Sci 1976, 274:652\u2013658.","journal-title":"Ann N Y Acad Sci"},{"key":"40_CR11","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/archneur.1996.00550080128020","volume":"53","author":"MJ Kuppersmith","year":"1996","unstructured":"Kuppersmith MJ, Moster M, Bhuiyan S, et al.: Beneficial effects of corticosteroids on ocular myasthenia gravis. Arch Neurol 1996, 53:802\u2013804.","journal-title":"Arch Neurol"},{"key":"40_CR12","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","volume":"62","author":"N Sommer","year":"1997","unstructured":"Sommer N, Sigg B, Melms A, et al.: Ocular myasthenia gravis: response to long term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 1997, 62:156\u2013162. Retrospective review 78 patients with OMG. Fifty patients were treated with prednisone or azathioprine. Only 12% of patients treated with an immunosuppressive agent developed generalized myasthenia versus 64% of patients not treated with immunosuppressive agent during a 2 to 4 year follow-up.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"40_CR13","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/(SICI)1097-4598(199909)22:9<1222::AID-MUS8>3.0.CO;2-R","volume":"22","author":"DH Weinberg","year":"1999","unstructured":"Weinberg DH, Rizzo JF, Hayes MT, et al.: Ocular myasthenia gravis: predictive value of single-fiber electromyography. Muscle Nerve 1999, 22:1222\u20131227. These authors performed a prospective study of 39 patients with OMG and reported the association of a normal SFEMG with myasthenia remaining restricted to the ocular muscles. 82% of patients with a normal SFEMG did not develop GMG after a minimum 2-year follow-up. However, an abnormal SFEMG was not predictive of progression to GMG; only 58% of patients with an abnormal SFEMG developed GMG during the follow-up period.","journal-title":"Muscle Nerve"},{"key":"40_CR14","unstructured":"Myopathies and disorders of neuromuscular transmission. In Walsh and Hoyt\u2019s Clinical Neuro-Ophthalmology, edn 5. Edited by Miller NJ, Newman N. Baltimore: Williams and Wilkins; 1998:1351-1460."},{"key":"40_CR15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1212\/WNL.48.Suppl_5.52S","volume":"48","author":"A Jaretzki","year":"1997","unstructured":"Jaretzki A: Thymectomy for myasthenia gravis: analysis of the controversies regarding technique and results. Neurology 1997, 48(suppl):52\u201363.","journal-title":"Neurology"},{"key":"40_CR16","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/jnnp.48.4.332","volume":"48","author":"F Schumm","year":"1985","unstructured":"Schumm F, Wierholter H, Gateh-Maoghadam A, Dichgans J: Thymectomy in patients with pure ocular myasthenia. J Neurol Neurosurg Psychiatry 1985, 48:332\u2013337.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"40_CR17","first-page":"837","volume-title":"Textbook of Ocular Pharmacology","author":"GI Wolfe","year":"1997","unstructured":"Wolfe GI, Barohn RJ, Galetta SL: Drugs for the diagnosis and treatment of myasthenia gravis. In Textbook of Ocular Pharmacology. Edited by Zimmeran TJ. Philadelphia: Lippincott-Raven Publishers; 1997:837\u2013848."}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-001-0040-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-001-0040-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-001-0040-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:56:44Z","timestamp":1559422604000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-001-0040-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,7]]}},"alternative-id":["40"],"URL":"https:\/\/doi.org\/10.1007\/s11940-001-0040-7","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,7]]}}}